Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
139
resultados
Última actualización
26/04/2026 [07:51:00]
Resultados 100 a 125 de 139
Resumen de: CN120945033A
The invention discloses a tissue resident bacterium marker for identifying normal colorectal tissue, polyp and intestinal cancer and application of the tissue resident bacterium marker. According to the present invention, the tissue resident bacterium markers comprise Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides, Collinsella and Parvimonas, and can be used to reflect the biological specificity of patients, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers; according to the present invention, with the combination model of the six bacteria such as Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides and Collinsella, the normal tissue and polyp of the colorectum can be accurately identified, and the accuracy is improved by 12.5% compared with the accuracy of the existing non-invasive screening method; the polyp and the intestinal cancer can be more accurately identified by a combined model of four bacteria, namely, Pseudomonas, Pigmentiphaga, F
Resumen de: WO2025232867A1
A method for detecting anxiety and/or depression metabolic and microbiome markers in a patient with irritable bowel syndrome (IBS) is provided. The method begins with obtaining a serum sample and a fecal sample from the patient. Both samples are processed to extract a gut metagenome, including a bacteriome, a mycobiome, and a virome of the patient, and metabolic features. A classifier is utilized to detect whether a marker set of microbial species and metabolites for depression and anxiety is present in the gut metagenome and the metabolic features.
Resumen de: WO2025233942A1
The present invention provides a system for diagnosing, treating, or both, a condition or a disease associated therewith, in a subject in need thereof, the system including a synthetic microbiome including recombinant cells. Further provided are a composition including the system, a kit, a method of using same.
Resumen de: CN120927854A
The invention discloses an exhaled gas VOC (volatile organic compound) marker for detecting inflammatory bowel diseases and a detection system thereof. The marker is a combination of one or more of the following components: methyl propyl sulfide, propionaldehyde, cyclohexanone, allyl methyl sulfide, octanal, 2-pentanone, phenol, butyric acid, propionic acid and 3-methylheptane. The detection system comprises an exhaled air sampling module, a sample preprocessing module, a detection analysis module and a data analysis module. The marker provided by the invention has the advantages of high specificity and good stability, can realize accurate noninvasive diagnosis of IBD, and can assist in realizing early screening and dynamic monitoring in a clinical environment.
Resumen de: CN120904133A
The invention provides an HClO activated diagnosis and treatment fluorescent prodrug as well as a synthesis method and application thereof, and the fluorescent prodrug has the Chinese name of 5-(3, 7-bis (dimethylamino)-10H-phenothiazine-10-formamido)-2-hydroxybenzoic acid. The invention also provides a synthesis method of the fluorescent prodrug. The fluorescent prodrug constructed by the invention can be specifically and rapidly activated by HClO (lt, 5min), releases near-infrared fluorophore methylene blue and a first-line drug 5-aminosalicylic acid for inflammatory bowel diseases, and has excellent specificity and sensitivity. In addition, response products are analyzed through high-resolution mass spectrometry, effective release of methylene blue and 5-aminosalicylic acid is proved, and feasibility of the compound serving as a prodrug for diagnosis and treatment of the inflammatory bowel disease is shown. According to the diagnosis and treatment fluorescent prodrug, non-invasive fluorescence imaging and treatment components are combined, and reasonable design and application of diagnosis and treatment integrated molecules are achieved.
Resumen de: CN120905354A
The invention relates to the field of genetic typing, and discloses a plectropomus leopardus generic genome typing method based on low-cost DNA extraction, which comprises the following steps: carrying out DNA sampling extraction on plectropomus leopardus to construct a re-sequencing library, processing DNA data of all high-depth groups in the re-sequencing library by using Shape software, constructing a haplotype database, and carrying out genotyping on the haplotype database. And performing genotype filling on the low-depth sequencing individuals to obtain haplotypes and genotypes of the low-depth sequencing individuals, and establishing a generic genome IBD cluster typing technology. And finally, generating an individual-level report of the target plectropomus leopardus. According to the invention, a lossless, simple and low-cost DNA extraction technology for the plectropomus leopardus can be established, large-scale sample application is realized, and the purpose of generic genome typing of the plectropomus leopardus is realized.
Resumen de: WO2025230979A1
Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting TNFAIP3 (e.g., hTNFAIP3); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the RNA agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing TNFAIP3 expression (e.g., mRNA expression), methods of treating TNFAIP3 associated diseases, and methods of treating proinflammatory (e.g., autoimmune) diseases (e.g., inflammatory bowel disease); and cancer.
Resumen de: US2025340627A1
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Resumen de: WO2025229605A1
New and useful computer-implemented methods; methods of identifying markers associated with enteropathies; methods of determining the level of severity of an enteropathy; and determining a treatment for an enteropathy; are disclosed. In addition, the present disclosure provides methods of identifying a biological response to one or more treatments for an enteropathy, and whether a given treatment to an enteropathy results in a therapeutic or adverse effect, as determined in a spatiotemporal manner throughout the entirety of the small bowel, or a region of interest therein.
Resumen de: WO2024189211A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: CN120958131A
Provided herein are methods for treating or preventing pouch inflammation comprising administering a SMAD7 antisense oligonucleotide or a pharmaceutical formulation comprising the SMAD7 antisense oligonucleotide.
Resumen de: CN120877279A
The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).
Resumen de: CN120882881A
The present invention relates generally to methods and diagnostic applications for treating ulcerative colitis. More specifically, the methods and diagnostic applications of the invention relate to the expression profiles of certain gene transcripts in ulcerative colitis patients and the use of the expression profiles of these gene transcripts for therapy and/or diagnosis in subpopulations of patients suffering from ulcerative colitis.
Resumen de: JP2025098004A
To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None
Resumen de: CN120859955A
The invention discloses a xylosidase response type chemiluminescent microsphere, a preparation method thereof and application of the xylosidase response type chemiluminescent microsphere in colitis in-situ diagnosis and treatment. The preparation method comprises the following steps: firstly, synthesizing a novel chemiluminescent probe specifically responsive to xylosidase and hyperbranched polyxylose targeting intestinal flora, then coupling the chemiluminescent probe and the hyperbranched polyxylose to prepare a functional diagnosis and treatment agent, and preparing the xylosidase responsive chemiluminescent microspheres through an electrospray technology. The xylose enzyme response type chemiluminescent microspheres provided by the invention can be delivered by oral administration, release a functional diagnosis and treatment agent in a pH environment of colon, monitor the activity of probiotics in the intestinal tract in vivo in situ, synchronously realize targeted regulation and control of the activity of the probiotics in the colon, and promote up-regulation of tight junction protein in the intestinal tract and tissue repair and regeneration.
Resumen de: WO2025226885A1
The present invention relates to a biomarker associated with intestinal inflammation, and more particularly, to methods for diagnosing or identifying a risk of developing intestinal inflammation using mitochondrial DNA and methods of treating disorders associated with intestinal inflammation.
Resumen de: WO2025224462A1
The invention relates to DNA methylation and gene expression signatures for assessing the severity of IBD in a patient, monitoring the progression of IBD in a patient, and/or determining the efficacy of a therapeutic agent for treating IBD in a patient. The DNA methylation and gene expression signatures of the invention can also be used for the differential diagnosis of Crohn's Disease or Ulcerative Colitis in a patient having or suspected of having IBD. The invention further relates to intestinal epithelial organoids (IEOs) for predicting the efficacy of therapeutic agents and for screening agents for use in treating IBD. The invention further relates to therapeutic agents for use in treating IBD.
Resumen de: US2025334593A1
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Resumen de: US2025332230A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Resumen de: CN120831477A
The invention discloses a novel target of PPP2R1A as an anti-inflammatory therapeutic drug and application of the novel target, it is found for the first time that knock-down of PPP2R1A can significantly inhibit expression of an anti-inflammatory active compound PB in NF-kB, TNF-alpha and IL-1beta inflammatory factors in human colon tumor cells, and at present, the relationship between PPP2R1A protein and inflammation has not been researched. The invention provides a novel drug target for treatment of inflammatory diseases in the field, provides a practical and effective screening method for discovery of inflammation treatment leading drugs, provides a scientific basis for clinical treatment of ulcerative colitis, and has a good application prospect in the aspect of anti-inflammation.
Resumen de: JP2025161855A
To provide compositions and methods useful in treating inflammation of the gut, such as inflammation associated with inflammatory bowel disease, by modulating γδ T cells (e.g., Vγ4+ cells).SOLUTION: Particular embodiments include: Vγ4+ cells expressing heterologous protein; polynucleotides containing genes contributing to functional expression of BTNL3, BTNL8, and HNF4A; methods of treating a subject using Vγ4+ cells or gene therapy; and methods of identifying a subject having mutations associated with inflammation of a gut. Compositions and methods of the invention can be used in treatment of inflammation and cancer of the gut.SELECTED DRAWING: None
Resumen de: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Resumen de: CN120818056A
The invention discloses an antibody or an antigen binding fragment capable of specifically recognizing and/or binding an anti-interleukin 6 receptor. Belongs to the field of antibody engineering. The antibody or the antigen binding fragment provided by the invention has higher biological activity, FcRn affinity and stronger antibody stability, and has a good clinical application prospect.
Nº publicación: CN120820665A 21/10/2025
Solicitante:
ZHEJIANG UNIV
\u6D59\u6C5F\u5927\u5B66
Resumen de: CN120820665A
The invention discloses a biomarker for identifying superior mesenteric artery dissection related intestinal dysfunction. The biomarker is lysophospholipid. By means of the biomarker, a patient with intestinal dysfunction caused by SISMAD can be recognized in an early stage, operation intervention (mainly stent implantation) can be conducted in time, and malignant consequences such as intestinal necrosis, large-area intestinal resection, short bowel syndrome and infection death are avoided.
BOPI
Sede Electrónica
